Illustrative image.

Rinvoq

Name: Rinvoq
Brand: Abbvie
Availability: InStock

Upadacitinib

Prescription required

$3231.00

15mg · 3 × 28 tablets · 3 months supply

BrandBranded medicine· By Abbvie

$1077.00 per month

Strength

How long a supply?

1 month$1077.00 a monthOne-off$1077.00

3 months$1077.00 a monthOne-off$3231.00

6 months$1077.00 a monthOne-off$6462.00

Supplied from Turkey

Test mode: no payment is taken. View cart

Annual cost

$14001a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

15mg

30mg

45mg

FDA boxed warningSerious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis

SERIOUS INFECTIONS

Patients treated with RINVOQ

/RINVOQ LQ

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

If a serious infection develops, interrupt RINVOQ

until the infection is controlled.

Reported infections include:

Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ

use and during therapy. Treatment for latent infection should be considered prior to RINVOQ

use.

Invasive fungal infections, including cryptococcosis and pneumocystosis.

Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

The risks and benefits of treatment with RINVOQ

should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with RINVOQ

, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

in patients that have experienced a myocardial infarction or stroke

THROMBOSIS

Thrombos

have occurred in patients treated

for inflammatory conditions

with J

inhibitors

, including RINVOQ

. Many of these adverse events were serious and some resulted in death.

In RA

patients

50 years of age and older with

least one cardiovascular

risk

in patients at risk.

discontinue RINVOQ

and

be promptly evaluated

Increased

(TB). Interrupt treatment with

RINVOQ

serious infection

occurs

Test

for latent

prior to

Monitor all patients for active

during treatment, even

patients with

initial negative

, latent TB test.

Read this with the rest of the clinical information

About Rinvoq

Overview

Rinvoq is a prescription extended-release tablet containing upadacitinib, a Janus kinase (JAK) inhibitor. It treats certain patients with rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis or giant cell arteritis. Eligibility depends on the condition and age; for most of these conditions, other specified treatments must have been ineffective, poorly tolerated or unsuitable. It works by blocking JAK enzymes that pass signals involved in immune cell activity.

What it treats

- Moderately to severely active rheumatoid arthritis in adults when one or more TNF blockers have not worked well enough or could not be tolerated. - Active psoriatic arthritis in adults and children aged 2 years and older when one or more TNF blockers have not worked well enough or could not be tolerated. - Moderate to severe atopic dermatitis in adults and children aged 12 years and older that remains uncontrolled by other systemic medicines, including biologics, or when those treatments are not advisable. - Moderately to severely active ulcerative colitis in adults when one or more TNF blockers have not worked well enough or could not be tolerated. If TNF blockers are not advisable, at least one approved systemic treatment must have been tried. - Moderately to severely active Crohn’s disease in adults, under the same prior-treatment conditions as ulcerative colitis. - Active ankylosing spondylitis in adults when one or more TNF blockers have not worked well enough or could not be tolerated. - Active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation when TNF blocker treatment has not worked well enough or could not be tolerated. - Active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older when one or more TNF blockers have not worked well enough or could not be tolerated. - Giant cell arteritis in adults.

Safety information

Side effects

Common side effects vary by the condition being treated. Reported effects include upper respiratory tract infections, bronchitis, cough, fever, headache, nausea, acne, rash, tiredness, abdominal pain, weight gain, muscle pain and swelling in the limbs. Shingles, herpes simplex infections, flu and inflammation around hair follicles have also been reported. Blood tests may show anemia, low white blood cell counts, increased liver enzymes, increased blood fats or increased creatine phosphokinase, a muscle enzyme. Your doctor may monitor these during treatment. Serious risks include serious infections, cancer and disorders involving abnormal growth of lymphatic cells, serious heart or blood vessel events, blood clots, severe allergic reactions and holes in the stomach or intestines. The label also warns of a risk of death. Contact a doctor promptly if you develop a serious infection or symptoms suggesting a serious reaction. Stop taking Rinvoq and seek immediate medical help if a severe allergic reaction occurs. Low blood sugar can occur in people with diabetes. Tell your healthcare provider if you develop signs or symptoms of low blood sugar; more frequent blood sugar monitoring may be needed.

FDA boxed warning

Serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis

SERIOUS INFECTIONS

Patients treated with RINVOQ

/RINVOQ LQ

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

If a serious infection develops, interrupt RINVOQ

until the infection is controlled.

Reported infections include:

Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ

use and during therapy. Treatment for latent infection should be considered prior to RINVOQ

use.

Invasive fungal infections, including cryptococcosis and pneumocystosis.

Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

The risks and benefits of treatment with RINVOQ

should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with RINVOQ

, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS

in patients that have experienced a myocardial infarction or stroke

THROMBOSIS

Thrombos

have occurred in patients treated

for inflammatory conditions

with J

inhibitors

, including RINVOQ

. Many of these adverse events were serious and some resulted in death.

In RA

patients

50 years of age and older with

least one cardiovascular

risk

in patients at risk.

discontinue RINVOQ

and

be promptly evaluated

Increased

(TB). Interrupt treatment with

RINVOQ

serious infection

occurs

Test

for latent

prior to

Monitor all patients for active

during treatment, even

patients with

initial negative

, latent TB test.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek urgent medical attention for fever with cough or unusual tiredness, which may signal an infection. - Get prompt medical attention for severe abdominal pain, as Rinvoq carries a warning about tears in the stomach or intestines.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not take Rinvoq if you have a known allergy to upadacitinib or any of its ingredients. Avoid use if you have an active, serious infection, including a localized infection. Rinvoq is not recommended for people with severe liver impairment. Conditions and precautions to discuss with your prescriber include: • Risk of a tear in the stomach or intestines (gastrointestinal perforation). Symptoms need prompt medical assessment. • Diabetes. More frequent blood glucose checks may be needed. Tell your healthcare provider if you develop symptoms of low blood sugar. • Changes in blood cell counts, hemoglobin, liver enzymes or blood fats. Laboratory monitoring is recommended. • Pregnancy or the possibility of becoming pregnant. Animal studies suggest Rinvoq may harm an unborn baby. Use effective contraception if you can become pregnant. • Breastfeeding. Do not breastfeed while taking Rinvoq. • Vaccinations. Avoid live vaccines during treatment. • Rapid passage of food through the digestive tract. Medication residue may appear in stool or ostomy output; your prescriber may consider another treatment if Rinvoq is not working adequately. Serious allergic reactions, including anaphylaxis, have been reported. Stop taking Rinvoq if a serious allergic reaction occurs.

Interactions

Tell your doctor if you take medicines classed as strong CYP3A4 inhibitors or strong CYP3A4 inducers. Strong CYP3A4 inhibitors may require a prescriber-directed dose adjustment when Rinvoq is used for atopic dermatitis, ulcerative colitis or Crohn’s disease. Taking Rinvoq with strong CYP3A4 inducers is not recommended.

Using Rinvoq

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label RINVOQ (UPADACITINIB) TABLET, EXTENDED RELEASE RINVOQ (UPADACITINIB) SOLUTION [ABBVIE INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.